- Home
- IPHA vs IPSC Comparison
IPHA vs IPSC Comparison
Compare IPHA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- IPSC
- Stock Information
- Founded
- IPHA 1999
- IPSC 2019
- Country
- IPHA France
- IPSC United States
- Employees
- IPHA N/A
- IPSC N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- IPHA Health Care
- IPSC Health Care
- Exchange
- IPHA Nasdaq
- IPSC Nasdaq
- Market Cap
- IPHA 178.0M
- IPSC 146.2M
- IPO Year
- IPHA 2019
- IPSC 2021
- Fundamental
- Price
- IPHA $2.07
- IPSC $1.10
- Analyst Decision
- IPHA Strong Buy
- IPSC Strong Buy
- Analyst Count
- IPHA 1
- IPSC 4
- Target Price
- IPHA $11.50
- IPSC $13.00
- AVG Volume (30 Days)
- IPHA 1.5M
- IPSC 864.2K
- Earning Date
- IPHA 09-12-2024
- IPSC 11-05-2024
- Dividend Yield
- IPHA N/A
- IPSC N/A
- EPS Growth
- IPHA N/A
- IPSC N/A
- EPS
- IPHA N/A
- IPSC N/A
- Revenue
- IPHA $36,202,722.00
- IPSC $2,684,000.00
- Revenue This Year
- IPHA N/A
- IPSC $230.56
- Revenue Next Year
- IPHA $102.87
- IPSC $31.85
- P/E Ratio
- IPHA N/A
- IPSC N/A
- Revenue Growth
- IPHA N/A
- IPSC 7.88
- 52 Week Low
- IPHA $1.29
- IPSC $0.98
- 52 Week High
- IPHA $3.51
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- IPHA 53.12
- IPSC 36.74
- Support Level
- IPHA $1.47
- IPSC $0.98
- Resistance Level
- IPHA $2.36
- IPSC $1.74
- Average True Range (ATR)
- IPHA 0.32
- IPSC 0.14
- MACD
- IPHA 0.06
- IPSC -0.04
- Stochastic Oscillator
- IPHA 29.99
- IPSC 15.79
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.